NCT05714553 - NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 8, 2023

Primary Completion Date

May 30, 2025

Study Completion Date

May 30, 2025

Conditions

Advanced CancerAdvanced Solid TumorNeoplasm MalignantMetastatic CancerMelanomaClassical Hodgkin LymphomaNon Small Cell Lung CancerRenal Cell CarcinomaUrothelial CarcinomaHead and Neck Squamous Cell CarcinomaSubungual Squamous Cell CarcinomaOesophageal CarcinomaMSI-H Colorectal CancerGastric CancerTriple Negative Breast CancerEndometrial CarcinomaPleural Mesothelioma

Interventions

DRUG

Fosifloxuridine Nafalbenamide

Intravenous infusion

DRUG

Leucovorin

Intravenous infusion

DRUG

Pembrolizumab

Intravenous infusion

DRUG

Docetaxel

Intravenous infusion

Trial Locations (4)

B15 2TH

Queen Elizabeth Hospital University Hospitals Birmingham NHS Foundation Trust, Birmingham

G12 0TN

The Beatson West of Scotland Cancer Centre, Glasgow

SE1 9RT

Guy's and St Thomas NHS Foundation Trust, London

M20 4BX

The Christie NHS Foundation Trust, Manchester